Table V.
Changes in bone mineral density and osteoporosis-related biomarkers with and without pharmacological treatment for osteoporosis.
| Variable | Medication | p-value* | |
|---|---|---|---|
| Yes (n = 88) | No (n = 310) | ||
| Mean T-score of femoral neck (SD) | -1.3 (1.2) | -1.0 (1.2) | 0.079 |
| Mean T-score of lumbar spine (SD) | -0.5 (1.6) | -0.1 (1.7) | 0.029 |
| Mean TRACP-5b, mU/dl (SD) | 393.6 (207.3) | 490.0 (207.2) | < 0.001 |
| Mean total P1NP, ng/ml (SD) | 58.7 (64.3) | 62.8 (30.8) | 0.402 |
| Mean homocysteine, nmol/ml (SD) | 10.8 (5.3) | 10.1 (8.9) | 0.471 |
| Mean intact PTH, pg/ml (SD) | 50.9 (35.5) | 53.1 (39.2) | 0.625 |
Medication: whether patients are using osteoporosis medication.
*
Independent-samples t-test.
P1NP, procollagen type 1 amino-terminal propeptide; PTH, parathyroid hormone; SD, standard deviation; TRACP-5b, tartrate-resistant acid phosphatase 5b.